ncRNA basic information ncRNA ID: MIMAT0000232 ncRNA Database: miRBase ncRNA Name: miR-199a-3p ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: RT-PCR ncRNA Target Gene: ITGB8 ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: The aim of the present study was to investigate the function and mechanism of miR-199a-3p in the CDDP resistance in ovarian cancer. We found that miR-199a-3p was significantly downregulated in chemoresistant ovarian cancer tissues, as well as CDDP-resistant SKOV3/CDDP cells, compared to chemosensitive carcinomas and SKOV3 cells. Restoration of miR-199a-3p in SKOV3/CDDP cells reduced cell proliferation, G1 phase cell cycle arrest, cell invasion, and increased cell apoptosis, resulting in enhanced CDDP sensitivity, while miR-199a-3p inhibition resulted in the opposite effects. Luciferase reporter assay showed that integrin Beta8 (ITGB8), one of the integrins that is involved in the regulation of cell cycle and motility, was a direct target of miR-199a-3p. Overexpression of miR-199a-3p downregulated ITGB8 expression via binding to its 3-UTR. In addition, overexpression of ITGB8 restored CDDP resistance inhibited by miR-199a-3p. Moreover, orthotopic ovarian cancer mouse model showed that miR-199a-3p enhanced CDDP sensitivity of ovarian cancer in vivo. Therefore, our results indicate that miR-199a-3p enhances CDDP sensitivity of ovarian cancer cells through downregulating ITGB8 expression, and miR-199a-3p may serve as a therapeutic target for the treatment of ovarian cancer patients with CDDP-resistance. Drug Response: sensitive

Cancer basic information Cancer: ovarian cancer Tissue/Cell: cell line (SKOV3,SKOV3/CDDP)

Other information Title: miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Journal: Oncol Rep Published: 2018 PubMed ID: 29436681